top of page

Dr. Heidi Noels and Dr. Yvonne Döring receive the W.H. Hauss Award from the DGAF

19-21 April 2018

Dr. Heidi Noels from the Institute for Molecular Cardiovascular Research at RWTH Aachen University together with Dr. Yvonne Döring from the Institute for Prophylaxis and Epidemiology of Circulatory Diseases at LMU Munich together received the DGAF W.H. Hauss Award 2018 from the German Society for Atherosclerosis Research (DGAF) during the 32nd Annual Meeting of the DGAF in Rauischholzhausen, Germany. They were awarded for their publication "Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies." (Circulation. 2017; 136: 388-403). In this work it could be shown that vascular CXCR4 has an atheroprotective function by maintaining the arterial integrity and preserving the endothelial barrier function. In addition, CXCR4 stabilizes a contractile smooth muscle cell phenotype. Targeted enhancement of these CXCR4-mediated protective functions could open up novel therapeutic options in the treatment of atherosclerosis.

The award was sponsored by a long-standing active member of the DGAF, Prof. Dr. Winfried März.

Project area Z

Administrative project

Robert Werner Mertens

MD student

University Hospital RWTH Aachen

Department of Internal Medicine

Project: The role of incretin hormone GLP-2 in septic cardiomyopathy

PI: Michael Lehrke

Robert Werner Mertens

MD student

University Hospital RWTH Aachen

Department of Internal Medicine

Project: The role of incretin hormone GLP-2 in septic cardiomyopathy

PI: Michael Lehrke

Consortium

Summerschool 2018

Mechanisms of Cardiovascular Complications

in Chronic Kidney Disease

Logo

Flyer

The SFB/TRR219 is supported by the German Research Foundation (DFG)

Project-ID 322900939

Clinical Studies Workshops 2025: the sequel

SFB/TRR219
Jul 7
1 min read

Following up on the first series of four workshops on clinical studies in 2024, we organized with our SFB/TRR219 IRTG a novel series of two online workshops on clinical studies in 2025.

Part 5: ‘The value of clinical biobank analysis – the UK biobank’ by Carolin Schneider, new PI in service project S-01 the applied 3^rd funding period of our SFB/TRR219
Part 6: ‘Biomarkers in Clinical Setting’ by Dr. Marlo Verket (M-03)

In this way, we continue our efforts to educate and train our basic scientists in medical knowledge.

Comments

bottom of page